Latest Product Development News

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Biotron Limited has completed a $1 million placement to fund the development of its newly acquired Sedarex Limited assets, marking a strategic expansion of its antiviral portfolio.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Oneview Healthcare reported robust commercial growth in 2025, driven by new US client wins and the launch of its AI-powered care assistant, Ovie. The company enters 2026 with a confident outlook focused on expanding its US footprint and advancing digital health innovation.

IMDEX Limited is set to acquire Advanced Logic Technology and Mount Sopris Instruments for nearly A$99 million upfront, significantly boosting its earth science sensor and software capabilities. The deal integrates industry-leading technologies and software, promising to accelerate IMDEX’s subsurface intelligence platform and market reach.

Papyrus Australia has marked significant progress at its Adelaide R&D facility while its sustainable fibre board gains international recognition, setting the stage for expanded global partnerships.

Cann Group Limited has successfully restructured its debt, stabilizing its finances and boosting operational performance, while appointing Mike Ryan as its new Chairman to guide future growth.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.